Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.72 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.72 |
| ▸ | NPC1 | O15118 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.71 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17406923 | 0.86 | KDM4E (0.76) | KDM4ETSHRMAPK1HTTHSD17B10 | |
| SCHEMBL2464129 | 0.84 | MEN1 (1.00) | KDM4ETSHRMAPK1HTTHSD17B10 | |
| SCHEMBL3157350 | 0.83 | MEN1 (1.00) | KDM4ETSHRMAPK1HTTHSD17B10 | |
| SCHEMBL8076506 | 0.83 | MEN1 (0.72) | KDM4ETSHRMAPK1HTTHSD17B10 | |
| SCHEMBL17609437 | 0.77 | POLB (0.68) | KDM4ETSHRMAPK1HTTHSD17B10 | |
| SCHEMBL8084587 | 0.75 | KMT2A (0.67) | KDM4ETSHRMAPK1HTTHSD17B10 | |
| SCHEMBL17406879 | 0.74 | KDM4E (0.59) | KDM4ETSHRMAPK1HTTHSD17B10 | |
| SCHEMBL8991109 | 0.74 | KDM4E (0.59) | KDM4ETSHRMAPK1HTTHSD17B10 | |
| SCHEMBL17620472 | 0.74 | MEN1 (0.65) | KDM4ETSHRMAPK1HTTHSD17B10 | |
| SCHEMBL8991414 | 0.73 | KDM4E (0.57) | KDM4ETSHRMAPK1HTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981968-B2 | Substituted pyrrolo[2,3-d]pyrimidines for the treatment of cancer and proliferative disorders | NORTHWESTERN UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981968-B2 | Substituted pyrrolo[2,3-d]pyrimidines for the treatment of cancer and proliferative disorders | NORTHWESTERN UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160002252-A1 | SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002252-A1 | SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2016-01-07 | — | — | US | disclosed |
| US-8883841-B2 | Oncogenic ras-specific cytotoxic compound and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-11 | — | — | US | disclosed |
| EP-1956910-B1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | UNIV TEXAS (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | KDM4E 3335/4885TSHR 4237/4885MAPK1 284/4885 |
| US-20160002252-A1 | SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | DPYD, TYMP, TYMS | KDM4E 2362/4885TSHR 3780/4885MAPK1 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.